Publications by authors named "Elizabeth C Howell"
Article Synopsis
- The study investigates AZD3965, a novel inhibitor of monocarboxylate transporter 1 (MCT1), intended to evaluate its safety and effectiveness in treating advanced cancers in patients with no standard treatment options.
- During the trial's dose escalation, 40 patients were treated, with common side effects including mild fatigue and changes in retinal function; dose-limiting toxicities mainly occurred at higher doses.
- The findings suggest that AZD3965 is generally well-tolerated at effective doses, establishing an optimal dosage of 10 mg twice daily for further testing in cancers with high MCT1 expression.
3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
Amarnath Challapalli Tara Barwick Rachel A Pearson Shairoz Merchant Francesco Mauri Elizabeth C Howell
Eur J Nucl Med Mol Imaging
May 2015
Purpose: 3'-Deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography (PET) has limited utility in abdominal imaging due to high physiological hepatic uptake of tracer. We evaluated FLT PET/CT combined with a temporal-intensity information-based voxel-clustering approach termed kinetic spatial filtering (FLT PET/CTKSF) for early prediction of response and survival outcomes in locally advanced and metastatic pancreatic cancer patients receiving gemcitabine-based chemotherapy.
Methods: Dynamic FLT PET/CT data were collected before and 3 weeks after the first cycle of chemotherapy.